Frontiers in Endocrinology, 2018 In addition to improving glucose metabolism, liraglutide, a glucagon-like peptide-1 receptor agonist, has weight-loss effects. The underlying mechanisms are not completely understood.
Li Zhao +7 more
doaj +1 more source
Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study [PDF]
, 2015 AIMS:Glucagon-like peptide 1 receptor agonists (GLP-1 RA) induce weight loss and reduction in adipose tissue, but the effects of GLP-1 RA on the distribution of fat deposits have been poorly investigated. METHODS: In 25 patients with type 2 diabetes (16
Carnevale, Vincenzo +9 more
core +1 more source
Liraglutide and renal outcomes in type 2 diabetes [PDF]
, 2017 In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks ...
Brown-Frandsen, Kirstine +9 more
core +2 more sources
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice [PDF]
, 2016 Diabetic patients suffer from a high rate of cardiovascular events and such risk increases with HbA1c. However, lowering HbA1c does not appear to yield the same benefit on macrovascular endpoints, as observed for microvascular endpoints. As the number of
Avogaro, Angelo +4 more
core +3 more sources
Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes:a substudy of the SUSTAIN 8 randomised, controlled clinical trial [PDF]
, 2020 Aims/hypothesis: Intra-abdominal or visceral obesity is associated with insulin resistance and an increased risk for cardiovascular disease. This study aimed to compare the effects of semaglutide 1.0 mg and canagliflozin 300 mg on body composition in a ...
Catarig, Andrei-Mircea +6 more
core +2 more sources
Molecular Medicine, 2023 Background Non-alcoholic fatty liver disease (NAFLD) is one of the most common complications of type 2 diabetes mellitus (T2DM). The pathogenesis of NAFLD involves multiple biological changes, including insulin resistance, oxidative stress, inflammation,
Tingli Guo +11 more
doaj +1 more source
VLED and formula LED in the management of type 2 diabetes: defining the clinical need and research requirements [PDF]
, 2011 It has been known for many years that substantial weight loss, achieved by bariatric surgery or non-surgical means can mean normalise glucose tolerance.
Lean, M.
core +1 more source
Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial [PDF]
, 2017 Objectives: This study sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients with heart failure and reduced ejection fraction.
Bolli, Geremia B. +7 more
core +2 more sources
Liraglutide improves pancreatic Beta cell mass and function in alloxan-induced diabetic mice. [PDF]
PLoS ONE, 2015 Glucagon-like peptide-1 (GLP-1) receptor agonists potentiate glucose-induced insulin secretion. In addition, they have been reported to increase pancreatic beta cell mass in diabetic rodents. However, the precise mode of action of GLP-1 receptor agonists
Kanako Tamura +5 more
doaj +1 more source
Liraglutide ameliorates diabetes-associated cognitive dysfunction via rescuing autophagic flux
Journal of Pharmacological Sciences, 2021 The incidence of diabetes–associated cognitive dysfunction is increasing. However, few clinical interventions are available to prevent the disorder.
Meng Zhang +10 more
doaj +1 more source